HOMBACH ROBERT J. 4
Research Summary
AI-generated summary
BioMarin (BMRN) Director Robert J. Hombach Receives 7,490 RSUs
What Happened
Robert J. Hombach, a director of BioMarin Pharmaceutical Inc., received a grant of 7,490 restricted stock units (RSUs) on June 2, 2026. The Form 4 reports the acquisition as 7,490 shares at $0.00; a footnote clarifies these are RSUs and a grant price is not applicable. This was an award/compensation grant rather than a purchase or sale.
Key Details
- Transaction date: 2026-06-02 (reported on Form 4 filed 2026-06-04)
- Transaction type/code: A — Award/Grant/Other acquisition
- Shares/units: 7,490 RSUs; filing shows $0.00 per share but footnote F1 notes price not applicable
- Shares owned after transaction: Not specified in the provided filing
- Footnote: F1 — "Restricted stock units granted on June 2, 2026. Price not applicable."
- Filing timeliness: Report filed two days after the transaction (appears timely)
Context
RSU grants are common director compensation and typically vest over time; they do not represent an immediate open‑market purchase or sale. Such awards are routine and do not, by themselves, indicate the director is buying or selling stock for directional reasons.